References
1. Munzel T, Gori T. Nebivolol: the somewhat-different beta adrenergicreceptor blocker. J Am Coll Cardiol 2009. 541491–1499.
2. Manrique C, Giles TD, Ferdinand KC, Sowers JR. Realities of newer beta-blockers for the management of hypertension. J Clin Hypertens (Greenwich) 2009. 11369–375.
3. Van Nueten L, Taylor FR, Robertson JI. Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomized trial. J Hum Hypertens 1998. 12135–140.
4. Czuriga I, Riecansky I, Bodnar J, Fulop T, Kruzsicz V, Kristof E, Edes I. For The NEBIS Investigators; NEBIS Investigators Group Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther 2003. 17257–263.
5. Van Nueten L, Schelling A, Vertommen C, Dupont AG, Robertson JI. Nebivolol vs enalapril in the treatment of essential hypertension: a double-blind randomized trial. J Hum Hypertens 1997. 11813–819.
6. Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens 2005. 181060–1066.
7. Wu KC, Gerstenblith S. Update on Newer Antihypertensive Medicines and Interventions. J Cardiovasc Pharmacol Ther 2010. 05. 1–11.
8. Rongen GA, Lenders JW, Smits P, Thien T. Clinical pharmacokinetics and efficacy of renin inhibitors. Clin Pharmacokinet 1995. 296–14.
9. Staessen JA, Li Y, Richart T. Oral renin inhibitors. Lancet 2006. 3681449–1456.
10. Brown MJ. Aliskiren. Circulation 2008. 118773–784.
11. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008. 3582433–2446.
12. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988. 332411–415.
13. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. Bosentan Hypertension Investigators. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med 1998. 338784–790.
14. Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Luscher TF. Long-term effect of darusentan on left-ventricular remodelling and clinical outcomes in the endothelin A receptor antagonist trial in heart failure (EARTH): randomized, double-blind, placebo-controlled trial. Lancet 2004. 364347–354.
15. Kirchengast M, Luz M. Endothelin receptor antagonists-Clinical realities and future directions. J Cardiovasc Pharmacol 2005. 45182–191.
16. Daull P, Jeng AY, Battistini B. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2007. 50247–256.
17. Rouleau JL, Pfeffer MA, Stewart DJ. Comparison of vasopeptidase inhibitor omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure. Lancet 2000. 356615–620.
18. Azizi M, Bissery A, Peyrad S. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans. Clin Pharmacol Ther 2006. 7949–61.
19. Drospirenone in HRT? Drug Ther Bull 2009. 4741–44.
20. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000. 6229–38.
21. White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005. 1121979–1984.
22. Perreault S, Lamarre D, Blais L, Dragomir A, Berbiche D, Lalonde L, Laurier C, St-Maurice F, Collin J. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother 2005. 391401–1408.
23. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, Volk HD, Stocker H, Müllter P, Jennings GT, Wagner F, Bachmann MF. Effect of immunization against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomized, placebo-controlled phase IIa study. Lancet 2008. 371821–827.